EN 简
About CARsgen
We focus on innovative CAR T-cell therapies

We are a biopharmaceutical company with operations in China and the U.S. focused on innovative CAR T-cell therapies for the treatment of hematological malignancies and solid tumors.

Read More
About CARsgen
Pipeline
Pipeline
Innovative and differentiated product pipeline

We develop innovative CAR-T technologies to empower the next generation pipeline products.

Read More
We have built an integrated cell therapy platform
<p>CycloCAR<sup>®</sup></p>

CycloCAR®

Cytokine and Chemokine Loaded CAR
<p>THANK-uCAR<sup>®</sup></p>

THANK-uCAR®

Allogeneic CAR-T platform
<p>LADAR<sup>®</sup></p>

LADAR®

Local Action Driven by Artificial Receptor
News Center
2023-05-18
CARsgen Initiates Phase 2 Clinical Trial for CLDN18.2 CAR T-cell Product CT041 in the U.S.
2023-05-05
CARsgen’s CLDN18.2 mAb AB011 Achieves IND Clearance from the NMPA for the First-line Combination Treatment of Gastric Cancer
2023-04-20
CARsgen’s CAR T-cell Candidate CT041 Achieves IND Clearance from the NMPA for the Postoperative Adjuvant Therapy of Pancreatic Cancer
2023-03-22
CARsgen Announced 2022 Annual Results and Business Updates
2023-01-31
CARsgen Announces Collaboration Agreement to Evaluate AB011 in Combination with PD-L1 Checkpoint Inhibitor to Treat Gastric Cancer
2023-01-20
CARsgen Presents Results on Anti-Claudin18.2-mAb AB011 at ASCO GI